Looking ahead

It's the administrative hearing on broader cannabis rescheduling — specifically, whether Schedule III status should extend beyond state-licensed medical and FDA-approved drug products to cover recreational and other currently-Schedule-I cannabis activity.

This is the proceeding that picks up where the Biden-era process collapsed in 2025. It runs through the standard DEA administrative pathway, not the treaty-route shortcut the April 23 order used. That means a full hearing record, expert testimony, public participation by designated parties, scientific evidence review — the long version of the process.

For OMMA-licensed medical operators, the hearing doesn't change anything in the current operating environment. Medical-side rescheduling already happened. The hearing is about whether to extend Schedule III to recreational cannabis, which Oklahoma doesn't have.

The hearing produces a record and a recommendation. It doesn't produce a final rule by itself.

What happens inside: scientific evidence on abuse potential and medical use, public-health considerations, regulatory experience under state programs, the eight-factor analysis. Designated participants — trade associations, advocacy groups, public-health organizations, state regulators — present testimony and evidence. The presiding administrative law judge produces a recommended decision based on the record.

What happens outside: the DEA Administrator decides whether to act on the recommendation. If she does, a proposed rule goes out for public comment. After comments are reviewed, a final rule is issued. Then any litigation challenges to that final rule begin.

The hearing is the first step in a multi-step process. The first step takes months. The full process takes years.

Years, not months. Here's the rough sequence:

• Hearing proceedings: June 29 to no later than July 15, 2026 (DEA's stated conclusion target)
• ALJ recommendation: 2 to 4 months after hearing closes
• Administrator decision on whether to publish a proposed rule: 1 to 3 months
• Notice-and-comment rulemaking: 6 to 12 months minimum
• Litigation against any final rule: separate 12-to-24-month track

Realistic earliest date for a final rule extending Schedule III to recreational: late 2027. More likely 2028. A change of administration in January 2029 could reset everything.

For OMMA-licensed operators, this means recreational rescheduling is not a near-term planning consideration. The medical-side regime you're operating under now is the operative one for the rest of 2026 and most of 2027 regardless of how the June 29 hearing goes.

Section 591 of the draft FY2027 Commerce-Justice-Science appropriations bill would prohibit the DEA from spending appropriated funds to advance cannabis rescheduling beyond the medical-side rule that's already in effect.

If the rider survives conference negotiations and is signed into law, it freezes the DEA's ability to spend on the June 29 hearing and downstream rulemaking — without changing the underlying legal authority to do the work. There are workarounds (internal reallocation, ALJ time as non-DEA staff time, hearing record at minimal marginal cost), but they slow the proceeding.

What the rider does not do: change anything about the existing medical-side rule, the Section 1301.13(k) registration pathway, or 280E relief. Those are settled. The rider is forward-looking — it would slow the broader rescheduling without touching what's already in force.

Watch the FY2027 conference timeline. A signed rider would push the broader rescheduling timeline outward by quarters.

The principal challenger is Smart Approaches to Marijuana (SAM), the most established prohibition-aligned advocacy organization with the capacity to mount sustained federal litigation. SAM has retained former Attorney General Bill Barr to lead its litigation strategy.

Likely co-plaintiffs include other drug-policy reform skeptics, some addiction-medicine professional associations, and possibly state attorneys general from states that opposed rescheduling.

The grounds:

• The treaty-route pathway under Section 811(d)(1) wasn't designed for downscheduling and using it that way exceeds the Attorney General's authority.
• Bypassing notice-and-comment rulemaking violates the Administrative Procedure Act.
• The administrative record is inadequate to support the substantive decision.
• HHS's scientific and medical evaluation, where required, wasn't performed.

This isn't a fringe lawsuit. The Barr involvement adds credibility, federal-litigation depth, and political complexity. Whether the merits succeed is a separate question — but the suit will be taken seriously.

Low for the order as a whole. Higher for specific implementation aspects.

For a court to block the entire order, the challengers would need to show both substantial likelihood of success on the merits and irreparable harm. Both are high bars given that courts give agencies meaningful deference when interpreting ambiguous statutes. Section 811(d)(1) is the kind of provision where reasonable agency interpretation gets weight.

Targeted injunctions against specific implementation pieces — particular registrations, particular FDA-jurisdiction questions, specific banking-treatment provisions — are more plausible if specific procedural defects are identified.

The base case is the order survives. Possibly with some modifications around the edges. Operators planning around the order should plan for it being in force; they should not bet against it.

This is the genuine downside-scenario question, and it deserves a direct answer.

Three plausible paths if a court overturns the order:

Prospective-only reversal. The order is overturned but the court doesn't disturb registrations or tax positions taken in good-faith reliance during the period the order was in effect. Operators absorb a return to Schedule I status going forward but don't face retroactive liability for what they did under the rule. This is the most likely reversal outcome.

Retroactive reversal. The court overturns the order and treats it as void from the beginning. Registrations void. 280E deductions disallowed. Significant practical disruption, though good-faith reliance defenses would generally be available. Lower probability.

Stay pending appeal. A court issues injunctive relief but stays its own order pending appeal, leaving the rule in effect during the appellate process. Operators continue under the rule with awareness of the litigation overhang. Procedurally common regardless of underlying merits.

The asymmetric calculation: the upside of registering (federal cover, banking access, 280E relief, federal commerce relationships) is large and current. The downside in a reversal scenario is real but manageable, and most reversal scenarios protect good-faith reliance. The base case is the order survives. Don't bet against it; do understand the downside.

Four scenarios worth holding in mind, with rough probability ranking for planning purposes:

Full survival (highest probability). The order stands without material modification. Medical-side rule operates as written. The June 29 hearing produces an eventual broader rule on the standard timeline. Banking and capital access progressively improve. This is the base case.

Narrow injunction or modification. Specific implementation aspects are modified by court order or further DEA action; the underlying scheduling change persists. Most likely modification targets: mixed-operator treatment, specific FDA-jurisdiction issues, or particular registration provisions. The medical-side core of the order survives.

Full overturn. The order is vacated on procedural or substantive grounds. Reverts cannabis to pre-April 23 federal status. Significant transitional disruption for operators who registered and reorganized. Lower probability than full survival but not negligible.

Congressional intervention. Congress acts to either codify the rescheduling (the most favorable outcome for the sector — converts agency rule into statutory law and eliminates litigation risk), preempt or override the order, or modify specific implementation through SAFE Banking or related legislation. Moderate probability over the 2026 to 2028 horizon.

These scenarios aren't mutually exclusive. A narrow injunction followed by congressional codification is a plausible composite outcome.

Mixed. Some structural protection, some real exposure.

Final rules survive administration change without affirmative repeal. A future administration can't simply rescind a final rule by executive fiat. Reversing the medical-side rescheduling would require either a new rulemaking to undo it (subject to its own procedural requirements and litigation exposure), congressional action, or a judicial decision invalidating it. None of those are fast.

That said, an administration disposed against the rule in 2029 has options. New rulemaking takes years but is feasible. Enforcement posture can shift overnight. Banking and capital-markets regulators can change examiner instructions.

The most durable insurance against future administrations would be congressional action codifying the rescheduling. That would convert the agency rule into a statute, which is materially harder to unwind. Whether Congress acts on this is the open political question of 2026 through 2028.

For operators making decisions today, the structural durability is real. The discretionary durability — how a future administration chooses to administer the rule — is less certain.